Posted on: 11th September 2018
Phase II Clinical Study in ADPKD Planned CALGARY, Alberta, Sept. 10, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company along with its collaborative partner, Cato Clinical Research, has submitted documents..More
Posted on: 22nd August 2018
QBie™ Spotlight joins Dr. Allen Davidoff, CEO, of XORTX Therapeutics Inc. (OTCQB: XRTXF), to discuss one of the OTCQB’s newest additions. XORTX joined the OTCQB on June 7, 2018. See the full article here (will open in a new tab).
Posted on: 13th August 2018
● Advancing to a Phase II Clinical Study in Polycystic Kidney Disease ● CALGARY, Alberta, Aug. 13, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company with its collaborative partner, Cato..More
Posted on: 28th June 2018
CALGARY, Alberta, June 28, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide the results of the Company’s annual and special meeting of shareholders and to provide a corporate update and summary of activities since..More
Posted on: 8th June 2018
CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company along with Cato Clinical Research has filed its pre-IND meeting request letter with the FDA. The request for a..More
Posted on: 6th June 2018
CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company’s shares have been approved to commence trading on the OTCQB Venture Market under the symbol XRTXF effective June..More
Posted on: 8th May 2018
CALGARY, AB – May 8, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Bruce Rowlands, a director of XORTX as Chairman of the Board of Directors. Bruce Rowlands has extensive experience in the..More
Posted on: 19th April 2018
CALGARY, AB – April 19, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease (“PKD”) and rare diseases such as autosomal dominant polycystic kidney disease (“ADPKD”)...More